Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and pIL-12 EP in Melanoma
NCT02493361Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2015
- Primary completion
- Apr 2018
- Countries
- 1
01
Overview
A Phase 2 trial of tavokinogene telseplasmid in melanoma, sponsored by University of California, San Francisco. Started Aug 2015; status: completed.
02
Drugs
tavokinogene telseplasmid
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02493361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493361.